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ARTÍCULO DE INVESTIGACIÓN
Finding of a novel fungal immunomodulatory protein coding sequence 
in Ganoderma australe
Hallazgo de una nueva secuencia codificadora para una proteína 
inmunomoduladora de origen fúngico en Ganoderma australe
Andrea González Muñoz*, Kelly Johana Botero Orozco**,  Germán Ariel López Gartner***
Abstract
Among the most common human diseases with immune system compromise are autoimmune diseases, cancer, and the 
acquired immunodeficiency syndrome (AIDS). Many of these diseases still have no treatment or their therapies have un-
desirable side effects. This has aroused a great interest in the search for new natural products with therapeutic potential 
and scientifically proven effects, showing minimal side effects. Formal clinical and pharmacological investigation in various 
medicinal fungi of the genus Ganoderma (Ganodermataceae) has shown immunomodulatory effects and tumor growth 
inhibition in mammals, attributable to the presence of immunomodulatory proteins and other secondary metabolites. To 
date, six fungal immunomodulatory proteins (FIPs) have been reported in Ganoderma. This paper seeks to advance in the 
discovery of immunomodulatory proteins present in Ganoderma australe, through mycelium transcriptome 454 Roche® 
pyrosequencing (RNA-seq) and bioinformatics analyses. The results suggest the presence of gene sequences related to an 
immunomodulatory protein which has been reported in another fungal species Taiwanofungus camphoratus. The candidate 
gene sequences found in G. australe exhibit high identity values in their amino acid composition and predicted protein 
secondary structure with the protein reported for Tai. camphoratus. According to present knowledge about the action 
mechanisms of these proteins, it is possible to suggest that this is a promising molecule for the treatment and prevention 
of diseases associated with certain immune deficiencies, cancer, and other diseases with compromised immune systems. 
Future studies are proposed in order to determine its immunomodulatory potential using in vitro and in vivo assays.
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Resumen
Enfermedades comunes como las autoinmunes, el cáncer y el síndrome de inmunodeficiencia adquirida aún no tienen 
tratamiento o sus terapias tienen efectos secundarios indeseables. Ello ha suscitado el interés en la investigación de 
bioproductos con potencial terapéutico, que no impliquen efectos secundarios. Investigaciones farmacológicas y clínicas 
en algunos hongos medicinales del género Ganoderma (Ganodermataceae) han comprobado efectos inmunomoduladores 
e inhibidores de crecimiento tumoral en mamíferos, atribuibles a la presencia de proteínas fúngicas inmunomoduladoras 
(FIPs) y otros metabolitos secundarios. Este trabajo busca avanzar en el descubrimiento de proteínas inmunomoduladoras 
presentes en Ganoderma australe, mediante la secuenciación del transcriptoma de micelio por tecnología de pirosecuen-
ciación 454 Roche® (RNA-seq) y análisis bioinformáticos. Los resultados sugieren la presencia de secuencias génicas rela-
cionadas con una proteína inmunomoduladora que se ha reportado en la especie de hongos Taiwanofungus camphoratus. 
Las secuencias génicas candidatas halladas en G. australe exhiben una altos valores de similitud en sus predicciones de 
composición aminoacídica y estructura secundaria proteica con la proteína reportada para Tai. camphoratus. Los meca-
nismos de acción de este tipo de proteínas inmunomoduladoras sugieren que se trata de una molécula con potencial 
promisorio para el tratamiento y prevención de enfermedades con compromiso del sistema inmunológico y el cáncer. 
Se proponen nuevos estudios que permitan determinar el potencial inmunomodulador de la proteína hipotética hallada 
mediante estudios in vivo e in vitro.
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Introduction
The Fungi kingdom is considered one of the great 
biodiversity resources, carrying out important roles in 
ecosystems and producing chemically diverse secon-
dary metabolites that contribute to a wide variety of 
bioactive properties in many fungal species. Therefore, 
fungi are promising resources for the discovery of no-
vel bioproducts with high potential for diverse biotech-
nological applications.
Interest in the use of therapeutic fungi has been his-
torically restricted to popular medicine and to the 
manufacture of dietary supplements with health bene-
fits. Moreover, until a few decades ago, the biological 
potential of these organisms stood as an unexploited 
resource in formal scientific investigation (Stamets, 
1993). However, scientific interest in fungi, as biolo-
gical resources with biotechnological and therapeutic 
applications, has increased considerably in the last few 
decades.
In particular, Ganoderma P. Karsten (1881) is a genus 
of ancient medicinal fungi, which has been used in 
traditional medicine for over 4,000 years (McMeekin, 
2004) and is considered a “spiritual herb” or “fungi 
of immortality” in oriental cultures. Within the genus, 
the species Ganoderma lucidum has been the object 
of interest of most pharmacological investigations. It 
has been proven that its extracts and pure biomolecu-
les inhibit cancer cell growth and promote an in vivo 
immune response through inducing immunoglobulin 
and cytokine production (Chang et al., 2009; Lin et al., 
2006); in addition, its metabolites can be effective anti-
virals against the human immunodeficiency virus (HIV) 
(Gao et al., 2003). Recently, one of these species’ 
bioactive therapeutic proteins has been cloned and 
efficiently expressed in molecular vectors (Wu et al., 
2013). Furthermore, other Ganoderma species have 
also been shown to be effective in diverse biotech-
nological applications for medicinal use. Ganoderma 
applanatum, G. tsugae, G. sinense, and G. microspo-
rum also promote antitumor and immunomodulatory 
activities (Jeong et al., 2008; Liao et al., 2008; Li et al., 
2010a; Lin et al., 2010), and G. australe has been repor-
ted to possess antimicrobial functions as well (Albino-
Smania et al., 2007). The most recent biotechnological 
applications in this genus include the development 
of recombinant fungal immunomodulatory proteins 
(Bastiaan-Net et al., 2013; Zhang et al., 2013) and na-
noparticle mycosynthesis for the directed modulation 
of antibiotic and antimicrobial (Karwa et al., 2011) and 
antitumor activities (Li et al., 2010a, 2010b).
Pharmacological and formal clinical studies on Gano-
derma have investigated its therapeutic activity with 
further detail and have scientifically evaluated its ca-
pacity for modulating the activation and expression 
of cells and messengers involved in the immune res-
ponse. This immunomodulation is mediated in part 
by proteins of the Fungal Immunomodulatory Protein 
(FIP) family, among other therapeutic secondary meta-
bolites. The biological function and action mechanisms 
of these proteins have been reported extensively in 
diverse studies (Li et al., 2011a; Li et al., 2010a; Lin, 
2005), classifying them as possible effective agents for 
treating and preventing diseases originated by certain 
immunodeficiencies and other states of immune dys-
function.
In general, mature FIPs have been defined as a family 
of proteins with a molecular weight of around 13 kDa, 
with 110 to 114 amino acid residues, and exist as ho-
modimers (Lin et al., 1997), except for FIP-gmi which 
is a tetramer (Wu et al., 2008). In addition, these pro-
teins exhibit a high structural and functional similarity 
with the immunoglobulin superfamily (Li et al., 2011a). 
Since the first FIP was isolated and characterized from 
G. lucidum (LZ-8) (Tanaka et al., 1989), its biological 
functions have been intensively explored and its DNA 
and protein sequences have served as references for 
the identification of new FIPs in other fungi, through 
homology hypotheses. To date, a total of nine FIPs 
have been reported from diverse basidiomycetes: FIP-
fve, from Flammulina velutipes (Ko et al., 1995); FIP-
vvo, Volvariella volvacea (Hsu et al., 1997); FIP-tve, 
Trametes versicolor (Li et al., 2011b); LZ-8, G. lucidum 
(Murasugi et al., 1991; Kino et al., 1989); FIP-gts, G. 
tsugae (Lin et al., 1997); FIP-gsi, G. sinense (Zhou et al., 
2007, 2009); FIP-gja, G. japonicum (GenBank acces-
sion AAX98241); FIP-gmi, G. microsporum (Wu et al., 
2007); and FIP-gap, G. applanatum (GenBank acces-
sion AEP68179).
The use of high-throughput genomic and transcripto-
me sequencing technologies has generated high vo-
lumes of biological information, and the increasing 
development of bioinformatics tools has built the way 
to finding and identifying novel genes related to pro-
teins of specific interest, as in the case of therapeutic 
proteins in fungi (Zhou et al., 2009). The main objecti-
ve of this work is to identify genetic sequences related 
to fungal immunomodulatory proteins in G. australe, 
through transcriptome sequencing (RNA-seq) by next 
generation sequencing technologies (454 Roche® 
pyrosequencing) and bioinformatics tools. We report 
the finding of a candidate coding sequence for an im-
munomodulatory protein in G. australe, exhibiting high 
sequence identity and secondary structure similarity to 
a reported immunomodulatory protein in Taiwanofun-
gus camphoratus. The results motivate further detailed 
biochemical and functional studies of this predicted 
hypothetical immunomodulatory protein.
Materials and Methods 
Fungal culture
A mycelium sample of Ganoderma australe grown on 
potato-dextrose agar (PDA) was received as a donation 
from the Universidad Tecnológica de Chocó, Colom-
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bia. For biomass production, the fungus was replicated 
on PDA and malt-extract agar (MEA). Then, these cul-
tures were used to inoculate a liquid culture medium 
enriched and optimized for Ganoderma, according to 
the protocol described by Zhou et al. (2007), in order 
to obtain a clean and pure sample for RNA extraction 
from mycelium.
cDNA library preparation
Total RNA extraction and messenger RNA (mRNA) pu-
rification, copy DNA (cDNA) library preparation, and 
454 GS FLX (Roche®) transcriptome sequencing was 
performed at the Centro Nacional de Secuenciación 
Genómica (CNSG), Sede de Investigación Universita-
ria (SIU), at the Universidad de Antioquia, Medellín, 
Colombia.
Total RNA extraction and mRNA purification from a 
mycelium sample of G. australe was done using the 
RNeasy Plant Mini Kit (Qiagen) and Oligotex mRNA 
Mini Kit (Qiagen), respectively, according to the 
manufacturer’s instructions. Total RNA and mRNA 
quantification was carried out on a TBS 380 fluorome-
ter (Turner Biosystems) and quality was determined 
through capillary electrophoresis on an Agilent 2100 
Bioanalyzer (Agilent Technologies).
Once optimal mRNA concentration and quality was 
determined, cDNA library preparation was done ac-
cording to the Roche® manufacturer protocol. Library 
quality was determined through capillary electropho-
resis (Agilent 2100 Bioanalyzer, Agilent Technologies) 
and sequencing was performed on half a plate of the 
454 Sequencing System GS FLX platform (Roche®).
De novo transcriptome assembly and 
bioinformatics analyses
Sequenced reads were assembled using the bioin-
fomatics algorithms employed by the Newbler 2.6 
assembler (Roche®). In order to identify mRNA trans-
cripts related to the expression of immunomodulatory 
proteins in G. australe mycelium, a local BLAST (tblastn) 
search was performed against a database of GenBank-
reported FIPs and other immunomodulatory proteins 
of other protein families, in order to broaden the search 
for immunomodulatory proteins in G. australe. Non-FIP 
family proteins were included if they belonged to fun-
gal species and showed significant alignment e-values 
and high sequence identities to the reported FIPs.
The transcripts with the highest identity to reported 
immunomodulatory proteins were selected for further 
bioinformatics analyses using online programs and ser-
vers, such as: Translate, for translating a DNA sequence 
to its six open reading frames and selecting the most 
probable coded protein (http://web.expasy.org/trans-
late/); MUSCLE (Edgar, 2004), for multiple alignments 
between the selected translated protein sequences 
and reported immunomodulatory proteins; Interpro, 
to predict protein domain architecture of the candi-
date translated sequences (http://www.ebi.ac.uk/in-
terpro/); and PSI-PRED v3.0, for predicting secondary 
protein structure (http://bioinf.cs.ucl.ac.uk/psipred/).
Results and discussion
A total of 712,683 raw reads were obtained from the 
transcriptome sequencing of the mycelium sample of 
G. australe. Preprocessing and quality control filtered 
679,023 reads that were used for de novo assembly. 
Table 1 summarizes the de novo assembly results.
Table 1. Summary of Ganoderma australe transcriptome 
sequencing and assembly.
Sequencing
Total reads 712,683
QC-passed reads 679,023
Amount of information 277 MB
De novo assembly
Total contigs 10,257
N50 (bpb) 918
Number of large contigsc 4,692
Mean size of large contigs (bp) 893
Largest contig size (bp) 4,933
a Quality control-passed 
b bp: base pairs 
c Contigs of at least 500bp
The search for transcripts (contigs) potentially related to 
immunomodulatory proteins allowed for the identifica-
tion of 24 initial candidate sequences showing significant 
alignments to non-FIP immunomodulatory proteins (data 
not shown). A further BLAST search against GenBank non-
redundant nucleotide and protein databases filtered 12 
of these transcripts, showing homology to non-FIP immu-
nomodulatory proteins reported in the basidiomycetes 
Trametes versicolor (GenBank Accession AGH06133.1) 
and Taiwanofungus camphoratus (GenBank Accession 
AAT11911.1), which were not included in our initial pro-
tein database, since they showed no significant hit to the 
FIP family. Although Trametes versicolor has a reported 
FIP, homology was found with a different non-FIP immu-
nomodulatory protein reported for this species.
Finally, only the transcripts with the highest identity 
were selected as definite candidates, which resulted in 
three candidate contigs: c2535 (e-value=3e-37), c725 
(e-value=1e-41), and c13717 (e-value=6e-48), with 
69%, 68%, and 66% identities, respectively, to the 
Tai. camphoratus protein. Subsequent analyses of the 
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confidence level, as represented by the height of the 
bars above the predicted structure (figure 3). Although 
secondary structure is not conclusive for determining 
protein function, it is nevertheless an indicator of a si-
milar folding pattern which could give insight into si-
milar structural motifs between the proteins, as well 
potential similar function.
Interestingly, the immunomodulatory protein from Tai. 
camphoratus was isolated by Sheu et al. (2009) from a 
mycelium extract and reported as a glycoprotein with 
a molecular weight of 27 kDa and 136 amino acid re-
sidues. Its immunomodulatory function is promoted 
through macrophage activation of a pro-inflammatory 
response (Sheu et al., 2009). Furthermore, it has been 
reported that this protein does not promote hemagglu-
tination in humans or mice (Sheu et al., 2009), which 
makes it promising for therapeutic application.
The immunomodulatory protein from G. australe, infe-
rred from contig c13717 in this study, as well as tho-
se reported from Tai. camphoratus and Tra. versicolor, 
show a predicted protein architecture composed of an 
18  amino acid residues signal peptide and a cerato-
platanin conserved domain, which is present in prote-
ins within the cerato-platanin protein family. This family 
contains phytotoxic proteins of approximately 150 ami-
candidates were performed in comparison to this par-
ticular Tai. camphoratus protein, due to showing higher 
identity values than the Tra. versicolor protein.
The selected contigs were translated to protein se-
quences (139 aa, 137 aa, and 137 aa for c2535, c725, 
and c13717, respectively) and a MUSCLE alignment 
was performed against the Tai. camphoratus immuno-
modulatory protein (figure 1). The alignment shows 
conserved sequence regions between the translated 
proteins and the reported protein. Furthermore, many 
mismatch positions included substitutions between 
amino acid residues with similar biochemical proper-
ties.
Secondary structure prediction of the hypothetical 
proteins showed high structural similarity between the 
three predicted proteins (figure 2). The protein from 
c13717 was further selected to be compared to the 
predicted secondary structure of the Tai. camphora-
tus immunomodulatory protein (figure 3), because it 
showed the highest prediction confidence level com-
pared to the other two candidates. Both G. australe 
c13717 and Tai. camphoratus proteins consisted of 
two α helices and seven b sheets, with the exception 
of a short additional b sheet in c13717, which was 
considered non-significant, due to a low prediction 
Figure 1. MUSCLE alignment between translated protein sequences of the candidate immunomodulatory proteins from Ganoder-
ma australe against the immunomodulatory protein sequence from Taiwanofungus camphoratus.
Figure 2. Predicted primary and secondary protein structures of the candidate immunomodulatory hypothetical proteins founded 
in Ganoderma australe. From left to right, blocks represent contigs: c13717, c725, and c2535, respectively. For each block: 1st row,  bars 
indicate confidence levels and a higher confidence level of the predicted structure is indicated by a greater height of the  bars. 2nd row, 
secondary structure predictions are indicated by two figures;  cylinders represent α helices,  arrows represent b sheets and straight 
lines represent random coils. 3rd row, strings of letters H, E and C, represent the same structures as in 2nd row, respectively. 4th row, 
amino acids are indicated individually by single letter code. 5th row, amino acid residues positions are numbered.
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no acid residues, with four cysteine residues that form 
two disulfide bridges contributing to protein structure 
(Pazzagli et al., 1999).  Indeed, the immunomodulatory 
protein predicted from G. australe is not, in a strict sen-
se, an immunomodulatory protein belonging to the FIP 
family, like other proteins previously reported for Gano-
derma. To this respect, strictly speaking FIPs have a mo-
lecular architecture composed of immunoglobulin-like 
beta-sandwich folds, characteristic of proteins within the 
immunomodulatory fungal family (FIP-fve), which is not 
the case with the G. australe protein reported in this stu-
dy.  Furthermore, the hypothesized G. australe protein 
exhibits substantial identity and structural similarity with 
the Tai. camphoratus protein,  and both contain methio-
nine, cysteine, and histidine residues that FIP-fve and LZ-
8-like prototypes do not contain. This evidence supports 
that the G. australe hypothetical protein reported and 
modeled in this work is not properly an immunomo-
dulatory protein belonging to the FIP family as traditio-
nally defined, like those reported in other Ganoderma 
species and other mushrooms, but rather a novel type 
of immunomodulatory protein with potentially similar 
functionalities based on its structure.
Finally, the observed homology of the hypothetical pro-
tein from G. australe with the immunomodulatory protein 
from Tai. camphoratus is an interesting finding from a ta-
xonomic perspective, since Tai. camphoratus has shared 
a taxonomic relation with the genus Ganoderma in the 
past. G. australe was initially described as Ganoderma 
comphoratum Zang & Su (1990), yet, due to morpholo-
gical aspects of the fruiting body, it was reclassified under 
the genus Taiwanofungus (Polyporaceae) in 1994, with 
Taiwanofungus camphoratus as the only species in this 
genus, endemic to Taiwan (Wu et al., 2004).
Further analyses should include the genomic sequen-
cing of G. australe and the in vitro testing of this se-
quence by means of molecular cloning of the complete 
gene into an appropriated vector, for example Pichia 
pastoris, or any other commercial expression vector, in 
order to further evaluate the therapeutic potential of 
the gene product through the implementation of pro-
tein recombination technology and bioassays approa-
ches using a model organism.
Conclusions
In this study, the presence of a candidate genetic se-
quence coding for a hypothetical immunomodulatory 
protein in the mycelium of Ganoderma australe is re-
ported. Moreover, transcriptome sequencing and as-
sembly performed in this study allow an estimation of 
at least 8,000 to 10,000 genes in G. australe. In order 
to confirm the presence of the predicted protein and 
experimentally determine its potential bioactive pro-
perties, future prospects include protein isolation and 
purification, recombinant expression, and possible in 
vitro and in vivo evaluations of the predicted immuno-
modulatory function.
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